PEPentwater Capital Management LP
Institutional investor · Portfolio as of Q1 2019
Top Holdings136 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
| 11.7M | $1.1B | 13.9% | — | — | — | New — | |
| 3.7M | $1B | 13.2% | — | — | — | New — | |
CELGENE CORP | 9.8M | $923.1M | 11.6% | — | — | 1 qtr | New 98 |
| 5M | $557.4M | 7.0% | — | — | — | New — | |
RED HAT INC | 1.8M | $322.5M | 4.1% | — | — | 1 qtr | New 86 |
TURQUOISE HILL RESOURCES LTD | 187.9M | $311.9M | 3.9% | — | — | 1 qtr | New 86 |
| 6.3M | $298.9M | 3.8% | — | — | — | New — | |
WELLCARE HEALTH PLANS INC | 1.1M | $290M | 3.7% | — | — | 1 qtr | New 85 |
| 1.4M | $221.9M | 2.8% | — | — | — | New — | |
NXP SEMICONDUCTORS NV | 2.4M | $214.1M | 2.7% | $79.22 | 0.00% | 1 qtr | New 79 |
WALT DISNEY CO/THE | 1.8M | $195.8M | 2.5% | $107.17 | 0.00% | 1 qtr | New 79 |
MELLANOX TECHNOLOGIES LTD | 1.6M | $185.8M | 2.3% | — | — | 1 qtr | New 79 |
| 2M | $172.8M | 2.2% | — | — | — | New — | |
| 3.6M | $133.6M | 1.7% | — | — | — | New — | |
ARRIS INTERNATIONAL PLC | 4.2M | $132.4M | 1.7% | — | — | 1 qtr | New 69 |
| 2.7M | $130.2M | 1.6% | — | — | — | New — | |
INTEGRATED DEVICE TECHNOLOGY INC | 2.6M | $128.8M | 1.6% | — | — | 1 qtr | New 69 |
P G & E CORP | 5.7M | $102.2M | 1.3% | $17.60 | 0.00% | 1 qtr | New 68 |
ESPERION THERAPEUTICS INC NE | 2.5M | $99.4M | 1.3% | $40.15 | 0.00% | 1 qtr | New 68 |
USCF Gold Strategy Plus Income | 2M | $86.3M | 1.1% | — | — | 1 qtr | New 68 |
Pentwater Capital Management LP manages $7.9B across 136 positions as of Q1 2019. Top holdings: CELGENE CORP (13.9%), STATE STREET SPDR S&P 500 ETF (13.2%), CELG (11.6%). Fund DNA: Momentum Trader. HoldingsIntel Rating: 2/5.0.
Active quarter - 104 new positions, 0 exits, 0 increased. Top move: CELG (NEW, conviction 98). Portfolio: $7.9B across 136 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer